Editorial Commentary
Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
Abstract
Lung cancer represents the main cause of cancer-related death globally. In recent years, the introduction of immune checkpoint inhibitors (ICIs) have changed prognosis in a relevant proportion of non-small cell lung cancer (NSCLC) patients, especially in immunogenic tumors, such as the smoke-related ones.
